tradingkey.logo

CareDx Inc

CDNA
查看詳細走勢圖
16.420USD
-1.050-6.01%
收盤 03/30, 16:00美東報價延遲15分鐘
16.63M總市值
虧損本益比TTM

CareDx Inc

16.420
-1.050-6.01%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-6.01%

5天

-4.26%

1月

-12.47%

6月

+10.50%

今年開始到現在

-12.85%

1年

-8.57%

查看詳細走勢圖

TradingKey CareDx Inc股票評分

單位: USD 更新時間: 2026-03-27

操作建議

CareDx Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名40/391位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為25.17。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

CareDx Inc評分

相關信息

行業排名
40 / 391
全市場排名
138 / 4542
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

CareDx Inc亮點

亮點風險
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
業績高增長
公司營業收入穩步增長,連續3年增長35.49%
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-41.87,處於3年歷史低位
機構加倉
最新機構持股52.64M股,環比增加0.08%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉88.35K股

分析師目標

基於 9 分析師
買入
評級
25.167
目標均價
+44.06%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

CareDx Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

CareDx Inc簡介

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
公司代碼CDNA
公司CareDx Inc
CEOHanna (John W)
網址https://www.caredx.com/
KeyAI